Physician profile
Jonathan K Cho
NPI 1174590541
$2,593.03
in general payments reported to CMS, 2019-2025
30 companies · $314 in 2025
The $314 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $731 · 2020: $976 · 2021: $363 · 2022: $54.86 · 2023: $127 · 2024: $25.97 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $467.71 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $424.12 | 2019-2020 | |
| Abbvie INC. | $317.34 | 2019-2024 | Venclexta |
| E.R. Squibb & Sons, L.L.C. | $223.43 | 2020-2021 | |
| Medtronic USA, INC. | $182.72 | 2020 | |
| Merck Sharp & Dohme LLC | $173.87 | 2019-2020 | |
| Pfizer INC. | $172.91 | 2019-2020 | |
| Caris Mpi, INC. | $155.76 | 2025 | Mi Cancer Seek |
| Geron Corporation | $122.98 | 2025 | Rytelo |
| Astrazeneca Pharmaceuticals LP | $107.43 | 2021 | |
| Janssen Biotech, INC. | $106.38 | 2019-2020 | |
| Amgen INC. | $92.23 | 2019 | |
| Novo Nordisk INC | $59.41 | 2020-2025 | Wegovy |
| Genentech, INC. | $57.48 | 2023 | |
| Seagen INC. | $48.49 | 2019-2020 | |
| Puma Biotechnology, INC. | $43.29 | 2019-2020 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Karyopharm Therapeutics INC. | $35.00 | 2020 | |
| Novartis Pharmaceuticals Corporation | $34.69 | 2022-2023 | |
| Kite Pharma, INC. | $33.60 | 2020-2022 | |
| Pharmacyclics LLC, An Abbvie Company | $31.74 | 2020 | |
| Bayer Healthcare Pharmaceuticals INC. | $22.91 | 2022 | |
| Genzyme Corporation | $20.86 | 2020 | |
| Deciphera Pharmaceuticals INC. | $20.54 | 2021 | |
| Aurobindo Pharma USA, INC. | $17.65 | 2020 | |
| Agios Pharmaceuticals, INC. | $17.17 | 2019 | |
| Eisai INC. | $13.51 | 2020 | |
| Taiho Oncology, INC. | $12.16 | 2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $12.15 | 2019 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| Epizyme, INC. | $11.50 | 2021 | |
| Secura Bio, INC. | $9.79 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Cho listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.